The Stanley Foundation Bipolar Treatment Outcome Network: I. Longitudinal methodology

Journal of Affective Disorders

Volumn 67, Issue 1-3, 2001, Pages 33-44

  Leverich, Gabriele S ^a,g   Nolen, Willem A ^b   Rush, A John ^c   McElroy, Susan L ^d   Keck Jr , Paul E ^d   Denicoff, Kirk D ^a   Suppes, Trisha ^c   Altshuler, Lori L ^e   Kupka, Ralph ^b   Kramlinger, Keith G ^f   Post, Robert M ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b Willem Arntsz Huis   (Netherlands)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Bipolar disorder; CGI BP; Clinical trials; Life chart; Longitudinal; Methodology; NIMH; Stanley Foundation Bipolar Network; Treatment

Indexed keywords

ARTICLE; DECISION MAKING; DEMOGRAPHY; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; FUNCTIONAL DISEASE; HUMAN; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL RESEARCH; METHODOLOGY; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; TREATMENT INDICATION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

BIPOLAR DISORDER; COMMUNITY NETWORKS; COMORBIDITY; ENDPOINT DETERMINATION; HUMANS; LONGITUDINAL STUDIES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0035719751     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(01)00430-X     Document Type: Article

References (65)

1. The bipolar spectrum: New concepts in classification and diagnosis
2. Criteria for the "soft" bipolar spectrum: Treatment implications
3. Switching from unipolar to bipolar II
4. Gabapentin in the acute treatment of refractory bipolar disorder
5. Current concepts of the classification of affective disorders
6. A brief history of bipolar disorder
7. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder
8. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
9. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder
10. The enduring psychosocial consequences of mania and depression
11. Preliminary evidence of the reliability and validity of the prospective life-chart methodology
12. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness
13. Bupropion versus desipramine for treatment of bipolar depression
14. Reliability and relationship of various ages of onset criteria for major affective disorder
15. The global assessment scale
16. A diagnostic interview: The schedule for affective disorders and schizophrenia
17. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders
18. Clinical Global Impressions
19. A rating scale for depression
20. Tranylcypromine versus imipramine in anergic bipolar depression
21. Expert consensus treatment guidelines for bipolar disorder: A guide for patients and families
22. The positive and negative syndrome scale (PANSS) for schizophrenia
23. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States
24. Coping strategies in psychiatric clinical research
25. Selection and utilization of outcome measures in psychiatric clinical trials. Report on the 1988 MacArthur Foundation Network I Methodology Institute
26. High rate of autoimmune thyroiditis and lithium associated hypothyroidism in bipolar disorder: No relation to rapid cycling
27. Life charting the course of bipolar disorder
28. The NIMH Life Chart Manual - Self Version™ (The NIMH-LCM™-S). Revised
29. The NIMH Life Chart Manual for recurrent affective illness: (The NIMH-LCM™). Revised
30. Life Charting of Affective Illness
31. Early physical or sexual abuse and the course of bipolar illness
32. Generalisability of results from randomized drug trials. A trial on antimanic treatment
33. The national depressive and manic-depressive association (DMDA) survey of bipolar members
34. Olanzapine in treatment-resistant bipolar disorder
35. Open-label adjunctive topiramate in the treatment of bipolar disorders
36. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder
37. The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests
38. Controversies in science: Consecutive patient questionnaire databases: A complementary alternative
39. Rapid cycling bipolar affective disorder: Lack of relationship to hypothyroidism
40. Special issues in trial design and use of placebo in bipolar illness
41. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers
42. The Stanley foundation bipolar network. I. Rationale and methods
43. NIMH Workshop report of treatment of bipolar disorder
44. National Institute of Mental Health Workshop Report on the Treatment of Bipolar Disorder
45. One-month prevalence of mental disorders in the United States: Based on five epidemiological catchment areas sites
46. The de facto US mental and addictive disorders service system: Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services
47. The inventory for depressive symptomatology (IDS): Preliminary findings
48. The inventory of depressive symptomatology (IDS): Psychometric properties
49. Methodological issues in developing new acute treatments for patients with bipolar illness
50. Bupropion versus desipramine for bipolar depression
51. Modifications of the clinical global impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP
52. Omega-3 fatty acids in bipolar disorder: A preliminary double-blind, placebo-controlled trial
53. Lamotrigine for the treatment of bipolar disorders; a clinical case series
54. An economic evaluation of manic-depressive illness-1991
55. A rating scale for mania; reliability, validity and sensitivity